[1] Smith R, Russell RG, Bishop M. Diphosphonates and Page's disease of bone [J]. Lancet, 1971, 1(7706): 945-947.
[2] Paterson AD, Kanis JA, Cameron EC, et al. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma [J]. Br J Haematol, 1983, 54(1): 121-132.
[3] van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.) [J]. Lancet, 1979, 1(8120): 803-805.
[4] Eastell R, Walsh JS, Watts NB, et al. Bisphosphonates for postmenopausal osteoporosis [J]. Bone, 2011, 49(1): 82-88.
[5] Reid IR. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies [J]. Skeletal Radiol, 2011, 40(9): 1191-1196.
[6] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [J]. J Oral Maxillofac Surg, 2003, 61(9): 1115-1117.
[7] Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper: Bisphosphonate-Related Osteonecrosis of the jaws--2009 update: the need to refine the BRONJ definition [J]. J Oral Maxillofac Surg, 2009, 67(12): 2698-2699.
[8] Siddiqi A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma [J]? Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2009, 108(3): e1-8.
[9] Bi Y, Gao Y, Ehirchiou D, et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice [J]. Am J Pathol, 2010, 177(1): 280-290.
[10] Sonis ST, Watkins BA, Lyng GD, et al. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients [J]. Oral Oncol, 2009, 45(2): 164-172.
[11] Pautke C, Kreutzer K, Weitz J, et al. Bisphosphonate related osteonecrosis of the jaw: A minipig large animal model [J]. Bone, 2012, 51(3): 592-599.
[12] Fournier P, Boissier S, Fileur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone stimulated vascular regrowth in the ventral prostate in castrated rats [J]. Cancer Res, 2002, 62(22): 6538-6544.
[13] Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover:a potential complication of alendronate therapy [J]. J Clin Endocrinol Metab, 2005, 90(3): 1294-1301.
[14] Arranz Caso JA, Flores Ballester E, Ngo Pombe S, et al. Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces [J]. Med Clin, 2012, 139(15): 676-680.
[15] Polizzotto MN, Cousins V, Schwarer AP. Bisphosphonate-associated osteonecrosis of the auditory canal [J]. Br J Haematol, 2006, 132(1): 114.
[16] Mavrokokki T, Cheng A, Stein B, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia [J]. J Oral Maxillofac Surg, 2007, 65(3): 415-423. |